AL HR166

Alabama Medicaid Agency is encouraged to evaluate potential savings from covering GLP-1 weight management medications, considering approximately 110,000 adult and child members may qualify based on current FDA labeling

Agency should assess overall costs in context of new federal drug pricing models from CMS, with participating manufacturers and medications expected to be announced by Spring 2026

Obesity affects 38.9% of Alabama adults and 15.6% of children in the WIC program, costing the state an estimated $7.2 billion in GDP impact and over $750 million annually to the state budget

Agency is encouraged to continue conversations with providers and stakeholders regarding improved health outcomes and cost savings

Findings must be reported to the Legislature prior to the 2027 Legislative Session